The Europe kidney disease market is expected to reach US$ 37,311.1 million in 2027 from US$ 23,121.5 million in 2019. The market is estimated to grow with a CAGR of 6.2% from 2020-2027.
Kidney disease is also known as renal disease. It is caused due to the malfunctioning of the kidney. There are various types of kidney diseases including kidney stones, glomerulonephritis, urinary tract infections, and others. For the treatment and diagnosis of these types of diseases, different global and regional players are offering various products and services. The scope of the kidney disease market includes product, end-user, and region.
Germany Kidney Disease Market Revenue and Forecasts to 2027 (US$ MN)

- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Market Insights
The Rise in the Private Insurance Sector
Every country in the European Union allows private health insurance to operate alongside publicly-financed (statutory) health insurance, but there is enormous diversity in the role private health insuranceplays within the health system and in the size and functioning of different markets for private health insurance. It is difficult to think of private health insurancein isolation from statutory health coverage, particularly in the European Union, where private health insuranceis never the only primary source of content. The dominance of statutory coverage means that markets for private health insuranceare heavily shaped by the rules and arrangements of the publicly-financed part of the health system.For example, complimentary private health insurancecan cover services excluded from the statutory benefits package, as in Ireland, where it is combined with supplementary private health insuranceand covers about 50% of the population (The Competition Authority 2007). Or it may reimburse the costs of statutory user charges, as in Slovenia and France, where it covers over 70% and 92% of the population respectively (Albreht et al. 2002; Durand-Zaleski 2008).Germany has a favorable reimbursement policy. For instance, VELTASSA, a prescription medication used to treat high potassium levels in the blood (hyperkalemia), has now secured reimbursement in Germany, following the AMNOG process (Price negotiation and arbitration process) in May 2019. Thus, the rise in the private insurance sector is likely to create lucrative opportunities for market growth.
Product- Based Market Insights
Based on product,thekidney disease marketis segmented into diagnosis and treatment. The diagnosis segment held the largest share of the market in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period.
Europe Kidney Disease Market, by Product – 2019 and 2027

- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
End-User - Based Market Insights
Based on end-user, the kidney disease market, is segmented into hospitals, diagnostic laboratories, and others. The hospitals segment held the largest share of the market in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period.
Customize This Report To Suit Your Requirement
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Europe Kidney Disease Market: Strategic Insights

- Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Europe Kidney Disease Market: Strategic Insights

- Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Product launches and approvals are commonly adopted strategies by companies to expand their footprint worldwide and meet the growing demand. The players operating in the kidney disease market adopt the expansion, collaboration, and product launch strategies to enlarge customer base across the world. These strategies allow the players to maintain their brand name globally. For instance,In July -2020, Bayer announced positive results from the Phase III FIDELIO-DKD study, assessing the efficacy and safety of finer none versus placebo when added to standard of care for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D), has met its primary endpoint.
EUROPEKIDNEY DISEASE MARKET SEGMENTATION
- Diagnosis
o Blood Tests
o Urine Tests
o Imaging Tests
o Others
- Treatment
o Dialysis
o Others
o Drug Class
- ACE Inhibitors
- Angiotensin-II Receptor Blockers
- Diuretics
- Others
By End User
- Hospitals
- Diagnostic Laboratories
- Others
By Country
- Europe
o Germany
o UK
o France
o Spain
o Italy
Company Profiles
- Abbott
- F. Hoffmann-La Roche Ltd
- AbbVieInc
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline plc
- Amgen Inc
- Sysmex Corporation
- Siemens AG
Europe Kidney Disease Market Regional Insights
The regional trends and factors influencing the Europe Kidney Disease Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Europe Kidney Disease Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

- Get the Regional Specific Data for Europe Kidney Disease Market
Europe Kidney Disease Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2019 | US$ 23,121.5 Million |
Market Size by 2027 | US$ 37,311.1 Million |
Global CAGR (2020 - 2027) | 6.2% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By Product
|
Regions and Countries Covered | Europe
|
Market leaders and key company profiles |
Europe Kidney Disease Market Players Density: Understanding Its Impact on Business Dynamics
The Europe Kidney Disease Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Europe Kidney Disease Market are:
- Abbott
- F. Hoffmann-La Roche Ltd
- AbbVieInc
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
Disclaimer: The companies listed above are not ranked in any particular order.

- Get the Europe Kidney Disease Market top key players overview
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.















The List of Companies - Europe Kidney Disease Market
- Abbott
- F. Hoffmann-La Roche Ltd
- AbbVieInc
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline plc
- Amgen Inc
- Sysmex Corporation
- Siemens AG


